Literature DB >> 4578567

Basis for loss of therapeutic effectiveness of L-asparaginase in sensitized mice.

S Baechtel, M D Prager.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4578567

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  4 in total

1.  Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase.

Authors:  J A Kidd; P Ross; A S Buntzman; P R Hess
Journal:  Vet Comp Oncol       Date:  2012-12-18       Impact factor: 2.613

2.  The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment.

Authors:  Gabriel J Wilson; Piyawan Bunpo; Judy K Cundiff; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-03       Impact factor: 4.310

3.  Effect of premedications in a murine model of asparaginase hypersensitivity.

Authors:  Christian A Fernandez; Colton Smith; Seth E Karol; Laura B Ramsey; Chengcheng Liu; Ching-Hon Pui; Sima Jeha; William E Evans; Fred D Finkelman; Mary V Relling
Journal:  J Pharmacol Exp Ther       Date:  2015-01-08       Impact factor: 4.030

4.  [Extracorporeal treatment with L-asparaginase (author's transl)].

Authors:  H Pralle; H Löffler
Journal:  Blut       Date:  1977-09-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.